⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
REGN News
Regeneron Pharmaceuticals Inc
AI-Driven Bispecific Antibody Development Attracts $1+ Billion in Pharma Investments Amid Clinical Risk Mitigation Focus
globenewswire.com
SNY
PFE
AMGN
REGN
Marquis Who's Who Interviews and Honors Guy Plunkett III, PhD, for Excellence in Bacteriology, Genomics and Higher Education
accessnewswire.com
ALGN
CRIS
REGN
GILD
AMGN
BIIB
VRTX
ILMN
NTLA
EDIT
EXAS
PACB
NVDA
AMD
INTC
MU
GOOG
MSFT
IBM
ORCL
CRM
ADBE
CSCO
ACN
BABA
JD
PDD
BIDU
IQ
HTHT
XPEV
NIO
LI
TSLA
RIVN
LCID
F
GM
STLA
VWAGY
TM
HMC
AGNC
PLTR
SNOW
DDOG
SMCI
ASML
KLAC
LRCX
AMAT
ADI
TXN
QCOM
MCHP
NXPI
ON
INFY
WIT
SAP
HPQ
DELL
MSI
AVGO
MRVL
WDC
SE
BILI
EDU
RLX
BEKE
TAL
Retinal Vein Occlusion Treatment Disease Market Size Worth USD 5.28 Billion by 2035, Expanding at a 6.44% CAGR – SNS Insider
globenewswire.com
REGN
ABBV
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
accessnewswire.com
REGN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
accessnewswire.com
REGN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
accessnewswire.com
REGN
O'Shaughnessy Ventures Backs Bioengineer Working to Cure Her Own Disease
prnewswire.com
REGN
Form 8-K
sec.gov
PBLS
REGN
Parabilis Medicines Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
globenewswire.com
REGN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
prnewswire.com
REGN